ABILIFY approved for acute treatment of bipolar I disorder in patients 10 to 17 years old

ABILIFY was discovered by Otsuka Pharmaceutical Co., Ltd. Founded in 1964, Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: “Otsuka - people creating new products for better health worldwide.” Otsuka researches, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for the treatment of diseases and consumer products for the maintenance of everyday health. Otsuka is committed to being a corporation that creates global value, adhering to the high ethical standards required of a company involved in human health and life, maintaining a dynamic corporate culture, and working in harmony with local communities and the natural environment. The Otsuka Pharmaceutical Group comprises

99 companies and employs approximately 31,000 people in 18 countries and regions worldwide. Otsuka and its consolidated subsidiaries earned U.S. $7.2 billion in annual revenues in fiscal 2006.

Bristol-Myers Squibb is a global biopharmaceutical and related healthcare products company whose mission is to extend and enhance human life.

For more information and FULL PRESCRIBING INFORMATION, including Boxed WARNINGS, visit: www.abilify.com

Visit Otsuka Pharmaceutical Co., Ltd. at: www.otsuka-global.com

Visit Bristol-Myers Squibb at: www.bms.com

* The Y-MRS is a standard measure that is an 11-item rating scale used by healthcare providers to assess the scope and severity of manic symptoms.(1) Y-MRS Total Scores range from 0 (no manic symptoms) to 60 (severe mania).(2)
*(1) Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity, and sensitivity. Br J Psychiatry. 1978; 133:429-435.
*(2) Rush AJ, et al. Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association;2000.

References

(1) Kumra S, Oberstar JV, Sikich L, Findling RL, McClellan JM, Vinogradov S, Schulz SC. Efficacy and Tolerability of Second-Generation Antipsychotics in Children and Adolescents With Schizophrenia. Schizophrenia Bulletin. Published online October 8, 2007.
(2) IMS Auditrac NGPS: ABILIFY total monthly retail prescriptions: Data accessed December 2007.

February 2008 0308N-0662

Additional Contacts

Hideki Shirai
Otsuka Pharmaceutical Co., Ltd

Sonia Choi/Communications
Bristol-Myers Squibb Company
Office: +1-609-252-5132

John Elicker/Investor Relations
Bristol-Myers Squibb Company
Office: +1-212-546-3775